AstraZeneca reported Phase 3 wins for its investigational COPD antibody in trials that showed success in broader-than-expected populations, following an earlier mid-stage failure. The company’s new data support continued development of the program despite the setback that had previously raised questions about responder selection. The update adds to an emerging pattern in respiratory drug development: late-stage efficacy can depend heavily on refined patient subgroups, endpoint definitions, or baseline biomarker stratification. AstraZeneca’s disclosures suggest it identified a population in which the mechanism and clinical effects align. For investors and competitors, the readout increases the likelihood of a renewed path to regulatory engagement, while also highlighting the importance of interpreting mixed earlier evidence through the lens of patient heterogeneity. The COPD antibody development track remains a bellwether for antibody utility in chronic respiratory disease, where safety and durable symptom improvements are key commercialization drivers.